Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822587 · ClinicalTrials.gov registry record · Phase 2
Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT01822587: Completed Phase 2 study, sponsored by Medical University of South Carolina.
NCT01822587 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 181 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01822587, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
The investigators' recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The investigators will attempt to augment this effect by a) doubling the number of propranolol-medicated cocaine cue exposure (CCE) retrieval sessions and b) increasing the dose of propranolol. It is expected that propranolol treated groups, relative to placebo treated groups, will evidence greater reduction of craving, cue reactivity and cocaine use during follow-up cocaine cue exposures. Also, these effects will be greater for those who receive 80mg of propranolol as opposed to 40mg.
Primary Outcome
Timeline of cocaine use throughout the duration of the study (in dollar amounts)
Interventions
- DRUG Placebo
- DRUG Propranolol, 40 mg
- DRUG Propranolol, 80 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-11-05 |
| Phase | Phase 2 |
What the finished NCT01822587 record still lists
NCT01822587 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01822587 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01822587 about?
NCT01822587 is a clinical study titled "Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving". The investigators' recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The investigator...
What is the current status of trial NCT01822587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2013-09. Estimated completion is 2018-11-05.
What interventions are being tested in trial NCT01822587?
The interventions under investigation include: Placebo (DRUG), Propranolol, 40 mg (DRUG), Propranolol, 80 mg (DRUG).
Who is sponsoring clinical trial NCT01822587?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01822587's enrollment target sits among peer trials
181 365th of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia